Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Immunogenicity and Safety of Quadrivalent Inactivated Split-Virion Influenza Vaccine in India
2022-001441-21Phase 3
- Sponsor
- Sanofi
- Start
- Jun 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3 trial of quadrivalent influenza vaccine in influenza, sponsored by Sanofi. Primary endpoint: Anti-hemagglutinin individual (HAI) titer.
02
Drugs
quadrivalent influenza vaccine
03
Conditions
influenza
Beyond the preview
Go deeper on 2022-001441-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-001441-21.